secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001213900-25-056415
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients
--------------------------------------------------------------------------------

- LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.
- CorMedix amended existing agreement with LDO customer to reflect anticipated increased product use.
- Q2 2025 net sales guidance raised from $31M to $35-40M; modest revenue contribution expected in June with growth through H2 2025.
- CEO cites implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025056415/0001213900-25-056415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025056415/ea0246261-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-056415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer